Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E Van Cutsem, A Cervantes, B Nordlinger… - Annals of …, 2014 - annalsofoncology.org
In 2012, there were 447000 new cases of colorectal cancer (CRC) in Europe. CRC is the
second most frequent cancer and represents 13.2% and 12.7% of all cancer cases in men …
second most frequent cancer and represents 13.2% and 12.7% of all cancer cases in men …
A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan+/− targeted therapy
DL Nielsen, JA Palshof, FO Larsen, BV Jensen… - Cancer treatment …, 2014 - Elsevier
Oxaliplatin, irinotecan and 5-fluorouracil in combination with or without targeted therapies
are well-documented treatment options for first-and second-line treatments of metastatic …
are well-documented treatment options for first-and second-line treatments of metastatic …
Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer
A Cercek, KA Goodman, C Hajj, E Weisberger… - Journal of the National …, 2014 - jnccn.org
Standard therapy for locally advanced rectal cancer (LARC) is preoperative
chemoradiotherapy and postoperative chemotherapy. At Memorial Sloan-Kettering Cancer …
chemoradiotherapy and postoperative chemotherapy. At Memorial Sloan-Kettering Cancer …
Colon cancer, version 3.2014
AB Benson, AP Venook, T Bekaii-Saab, E Chan… - Journal of the National …, 2014 - jnccn.org
The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical
management, perioperative treatment, posttreatment surveillance, management of recurrent …
management, perioperative treatment, posttreatment surveillance, management of recurrent …
Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer
CM Hocking, TJ Price - Therapeutic advances in …, 2014 - journals.sagepub.com
The past 15 years has seen a marked increase in available therapeutic options for patients
with metastatic colorectal cancer resulting in improvements in median survival from 12 to 24 …
with metastatic colorectal cancer resulting in improvements in median survival from 12 to 24 …
miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor
M Pichler, E Winter, AL Ress, T Bauernhofer… - Journal of clinical …, 2014 - jcp.bmj.com
Aims miR-181a expression is frequently altered in different types of cancer. Members of the
Wnt/β-catenin signalling pathway, which is commonly altered in colorectal cancer (CRC) …
Wnt/β-catenin signalling pathway, which is commonly altered in colorectal cancer (CRC) …
[HTML][HTML] Elderly patients with colorectal cancer: treatment modalities and survival in France. National data from the ThInDiT cohort study
S Doat, A Thiébaut, S Samson, P Ricordeau… - European Journal of …, 2014 - Elsevier
Background Few data exist on how elderly patients with colorectal cancer (CRC) are
actually treated in real-life practice. Based on a national cohort, we analysed routine …
actually treated in real-life practice. Based on a national cohort, we analysed routine …
Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer
RJ Myerson, B Tan, S Hunt, J Olsen, E Birnbaum… - International Journal of …, 2014 - Elsevier
Background Preoperative radiation therapy with 5-fluorouracil chemotherapy is a standard
of care for cT3-4 rectal cancer. Studies incorporating additional cytotoxic agents …
of care for cT3-4 rectal cancer. Studies incorporating additional cytotoxic agents …
Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil …
V Formica, J Luccchetti, D Cunningham, EC Smyth… - Medical Oncology, 2014 - Springer
The inflammatory index neutrophil/lymphocyte ratio (NLR) has an adverse prognostic value
in patients with localized colorectal cancer (CRC). We aimed at evaluating its role in …
in patients with localized colorectal cancer (CRC). We aimed at evaluating its role in …
Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy
The bottlenecks of current chemotherapy in the treatment of colorectal cancer lie in the
ineffectiveness of the existing anti-cancer small molecule drugs as well as the dose-limiting …
ineffectiveness of the existing anti-cancer small molecule drugs as well as the dose-limiting …